Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ultragenyx Pharmaceu (NQ: RARE ) 56.36 -0.69 (-1.21%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ultragenyx Pharmaceu < Previous 1 2 3 4 5 6 7 8 9 Next > Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) August 21, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs August 06, 2024 Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells. Via Benzinga Topics Lawsuit Exposures Financial Legal 3 Genomics Stocks That May Transform Personalized Medicine August 06, 2024 These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry. Via InvestorPlace Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update August 01, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical July 22, 2024 Via Benzinga Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights May 31, 2024 Via Benzinga Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update July 25, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium July 24, 2024 Presentations will include an encore of the positive interim Phase 1/2 results presented in April at the 76th Annual American Academy of Neurology (AAN) Meeting From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst July 22, 2024 Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... Via Benzinga Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong July 22, 2024 Biogen previously decided against opting into Ionis' Angelman program. Via Investor's Business Daily Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) July 19, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program July 17, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 20, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire 7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline June 17, 2024 With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. Via InvestorPlace Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 14, 2024 Via Benzinga Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants June 13, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session June 13, 2024 Via Benzinga Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants June 12, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) June 12, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) June 11, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday June 06, 2024 Via Benzinga Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) May 30, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells May 22, 2024 The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against... Via Benzinga Topics Lawsuit Exposures Financial Legal Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 17, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference May 07, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024 May 02, 2024 RARE stock results show that Ultragenyx Pharmaceutical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update May 02, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease April 30, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) April 30, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.